Other

Beijing Betta Pharmaceuticals Co., Ltd

Fujian Haixi Pharmaceuticals Co., Ltd

Betta Pharmaceuticals Co., Ltd.

Fujian Haixi Pharmaceuticals, Inc.

Betta Pharmacueticals Co., Ltd.

Kang, Xinshan

Xinshan Kang

Wei Long

Yunyan Hu

Yinxiang Wang

Yanping Wang

Cunbo Ma

Fenlai Tan

Yan Feng

Hong Cao

Xuan Gong

Ruyong Wang

Fei Wang

Xiaoyan Shen

Liufeng Zhou

Yizhang Ye

Fengsen Zhang

Jianxi Zhang

Zhonghong Wang

Xin Lian

Jianjia Zheng

Yueli Fu

Junqing Li

Provided herein are compounds of formula (I) having activity on a receptor protein tyrosine kinase, wherein R, R, R, A, Q, Z, X and W are set forth in the description, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof.

Heteroaryl compounds as kinase inhibitor

The present application provides a compound in formula III, and further provides a use of the compound in the synthesis of a Brivaracetam intermediate and a crude drug, and a synthesis method. A raw material involved in the method of the present application is low in costs and easily available; (R)-4-propyl-dihydrofuran-2-ketone having high optical purity can be prepared; complicated separation and purification steps are avoided; costs are reduced, and the method is more applicable to industrial production. 

Compound and use thereof in synthesis of brivaracetam intermediate and crude drug

The compound of Formula (I), pharmaceutically acceptable salts thereof, solvates thereof, chelates thereof, non-covalent complexes thereof or produgs of compounds mentioned above or the mixture of any form above mentioned are provided. The use of the compounds in manufacturing a medicament for the treatment and/or prevention of diabetes, obesity and related disorders. 

Compound for increasing kinase active and application thereof

The polymorphic forms of the compound of Formula I, the preparation thereof including the preparation of the intermediates, the pharmaceutical compositions thereof and the uses of a polymorph above in the manufacture of medicaments for treating a disease, a disorder or a condition are disclosed. 

Stable polymorphic forms of compound as hypoxia mimetics, and uses thereof

The present invention relates to the polymorphic forms of the compound of Formula (I), preparation thereof including the preparation of intermediates and pharmaceutical compositions, and use of a polymorph above in the treatment of a disease, a disorder or a condition, or in the manufacturing of a medicament for the treatment of a disease, a disorder or a condition. 

Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof

This invention relates to new compounds that can serve as hypoxia mimetics. This invention also relates to methods of increasing HIF levels or activity in a subject or treating a condition associated with HIF levels or activity in a subject by administering to the subject at least one of these compounds.

Compounds as hypoxia mimetics, and compositions and uses thereof

Growing community of inventors

Beijing, China

Xinshan Kang